07.08.2012 • Product

Planning tool for industrial water treatment

Lanxess launches a new planning tool for the industrial water treatment. The LewaPlus design software is a tool for ion exchange resins (IX) and reverse osmosis (RO) membrane systems. LewaPlus allows for dimensioning of IX and RO systems under a variety of system configurations, including some unique process configurations.

The LewaPlus software provides a number of benefits to the designer:
• A new user interface to assist in organization of design project files, and linkage to data sheets and MSDS documentation (for IX)
• A single water analysis data entry screen, with RO scaling calculations, suitable for both IX and RO applications
• Advanced RO system configuration options with automatic calculation of a recommended array for optimization of system sizing
• Immediate calculation of system performance, including feed pressure calculations and permeate quality on a single screen in the RO module
• Output of IX and RO system design parameters and effluent (permeate) quality in an easy to manipulate printed output

The LewaPlus software also allows the designer to conduct both IX and RO designs inside the same program utilizing the same feed water, allowing seamless design of RO permeate to IX feed, or a direct comparison of dimensioning requirements of either technology.

 

Company

LANXESS Deutschland GmbH

Kaiser-Wilhelm-Allee 40
51369 Leverkusen
Germany

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read